Shuangcheng Pharmaceutical issued an indicative notice on abnormal stock trading fluctuations and risks. After self-inspection, the company did not violate fair disclosure of information. The company is planning major asset restructuring matters. On September 10, 2024, the company held the 15th meeting of the 5th board of directors and the 14th meeting of the 5th board of supervisors to review proposals related to this transaction, such as the “Proposal on the Company's Issuance of Shares and Payment of Cash to Purchase Assets and Raise Supporting Funds and Related Transactions”. The audit and evaluation of this transaction has not yet been completed, and the specific transaction price of this transaction has not yet been determined. The transaction still needs to be reviewed again by the company's board of directors and reviewed and approved by the company's shareholders' meeting, and can only be officially implemented after approval by the relevant supervisory authorities. There is still some uncertainty about whether it can pass the approval.

Shuangcheng Pharmaceutical issued an indicative notice on abnormal stock trading fluctuations and risks. After self-inspection, the company did not violate fair disclosure of information. The company is planning major asset restructuring matters. On September 10, 2024, the company held the 15th meeting of the 5th board of directors and the 14th meeting of the 5th board of supervisors to review proposals related to this transaction, such as the “Proposal on the Company's Issuance of Shares and Payment of Cash to Purchase Assets and Raise Supporting Funds and Related Transactions”. The audit and evaluation of this transaction has not yet been completed, and the specific transaction price of this transaction has not yet been determined. The transaction still needs to be reviewed again by the company's board of directors and reviewed and approved by the company's shareholders' meeting, and can only be officially implemented after approval by the relevant supervisory authorities. There is still some uncertainty about whether it can pass the approval.